We are live on ! Find out more
TLIS

Talis Biomedical Corporation Common Stock
TLIS

Delisted

TLIS was delisted on the 30th of August, 2024.

Back to rankings

1 hedge funds and large institutions have $26 invested in Talis Biomedical Corporation Common Stock in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% less funds holding

Funds holding: 2 → 1 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

100% less capital invested

Capital invested by funds: $460K → $26 (-$460K)

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SAM
Synergy Asset Management
Washington
+$26

Top Sellers

Rank Fund Capital Flow
1
BCM
BML Capital Management
Indiana
-$460K
2
SPIA
Steward Partners Investment Advisory
New York
-$272
Name Holding Trade Value Shares
Change 		Change in
Stake
SAM
1
Synergy Asset Management
Washington
$26 +$26 +14 New
BCM
2
BML Capital Management
Indiana
– -$460K -248,702 Closed
SPIA
3
Steward Partners Investment Advisory
New York
– -$272 -147 Closed

TLIS Hedge Fund Activity: Q4 2024 in Review

1 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Talis Biomedical Corporation Common Stock (TLIS) for Q4 2024, worth a combined $26 — down 100% from $460K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of TLIS and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was Synergy Asset Management, opening a new position worth an estimated $26. The largest seller was BML Capital Management, exiting entirely with an estimated $460K sold.

  • 1 institutional investor held Talis Biomedical Corporation Common Stock (TLIS) as of Q4 2024, down from 2 in Q3 2024.
  • Funds reported $26 of Talis Biomedical Corporation Common Stock stock for Q4 2024, down 100% quarter-over-quarter.
  • 1 fund opened new Talis Biomedical Corporation Common Stock positions in Q4 2024 and 2 closed out, a net change of -1 holder.
  • The largest Talis Biomedical Corporation Common Stock buyer in Q4 2024 was Synergy Asset Management, an estimated $26 added.
  • The largest Talis Biomedical Corporation Common Stock seller in Q4 2024 was BML Capital Management, an estimated $460K sold.

Based on aggregated 13F filings for Q4 2024.